Updates in osteoporosis medications: maximizing benefits and minimizing risks
American Journal of Medicine Open · 2026-12 · 16 · 100142
DOI: 10.1016/j.ajmo.2026.100142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Medicine Open, 2026-12. Verfasst von Keity M Okazaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Fonds de recherche du Québec, Université de Montréal.
Abstract (Originalsprache)
Osteoporosis is a major public health concern affecting approximately 1 in 3 women and 1 in 5 men over the age of 50 globally. Hip fractures are a significant complication of osteoporosis and are associated with approximately 20%-24% mortality in the year after fracture. While medications can substantially reduce fracture risk, these therapies remain significantly underutilized. This treatment gap is partly driven by confusion among healthcare professionals and patients regarding potential treatment complications. This narrative review provides a practical overview of strategies to maximize benefits and minimize risks of pharmacologic osteoporosis therapies, including calcium/vitamin D, bisphosphonates, denosumab, parathyroid hormone (PTH) analogs, romosozumab, raloxifene, and menopausal hormone therapy (MHT). In addition to reviewing the latest data about therapeutic efficacy and safety, we provide a summary of best practices to mitigate potential side effects. Relevant updates include new data on the efficacy of bisphosphonates in lower risk patients, recommendations for using osteoanabolic agents as first-line for very high fracture risk patients, important considerations regarding multiple vertebral fractures when discontinuing denosumab, as well as cardiovascular safety data and the option of a shortened course for romosozumab. FDA updates are highlighted: removal of the osteosarcoma black-boxed warning for PTH analogs, nuances in the warnings regarding MHT, and addition of a black-boxed warning for severe hypocalcemia with denosumab in chronic kidney disease. The benefits of osteoporosis medications in preventing high-morbidity fragility fractures significantly outweigh the small risks of serious complications. It is essential for clinicians to understand the myths and realities of these treatments and to implement mitigation strategies to ensure patient safety. By effectively addressing these issues, healthcare professionals can play a vital role in closing the osteoporosis treatment gap.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
Förderung
- NIDDK NIH HHS
- Fonds de recherche du Québec
- Université de Montréal
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Okazaki, K. M., Wang, J. Y., & Yu, E. W. (2026). Updates in osteoporosis medications: maximizing benefits and minimizing risks. American Journal of Medicine Open, 16, 100142. https://doi.org/10.1016/j.ajmo.2026.100142
Vancouver
Okazaki KM, Wang JY, Yu EW. Updates in osteoporosis medications: maximizing benefits and minimizing risks. American Journal of Medicine Open. 2026;16:100142. doi:10.1016/j.ajmo.2026.100142
BibTeX
@article{Okazaki2026,
author = {Okazaki, Keity M and Wang, Jane Y and Yu, Elaine W},
title = {Updates in osteoporosis medications: maximizing benefits and minimizing risks},
journal = {American Journal of Medicine Open},
year = {2026},
volume = {16},
pages = {100142},
doi = {10.1016/j.ajmo.2026.100142}
}
EUVIMED